Rotavirus vaccines kill cancer cells Researchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines. more ➔
Polyphor presents AMR breakerSwiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics. more ➔
Zealand Pharma acquires EncycleZealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library. more ➔
Researchers target ferroptosis resistance...German researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer. more ➔
CHMP selects drugs for EU market approvalEMAs human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting. more ➔
New risk factor for autism and epilepsy id...A molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders. more ➔
Healx Ltd raises $56m in Series B financin...AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases. more ➔
4SC expands domatinostat combo testingThe Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-naive melanoma patients. more ➔
Cell transdifferentiation specialist Mogri... British start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the round, … more ➔
Patient’s organoids predict response... A new test based on tumour organoids can predict how patients with advanced colorectal cancer respond to chemotherapy treatment. more ➔
